SEC Company Response from BriaCell Therapeutics Corp. (BCTX, BCTXL, BCTXZ) (CIK 0001610820) (BCTX) — May 15, 2020
BriaCell Therapeutics Corp. (BCTX, BCTXL, BCTXZ) (CIK 0001610820)
Date: May 15, 2020 · CIK: 0001610820 · Accession: 0001493152-20-009239
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-234292
Letter
BriaCell Therapeutics Corp.
Suite 300 – 235 West 15th Street
West Vancouver, BC V7T 2X1
Securities and Exchange Commission
F Street N.E.
Washington, D.C. 20549
Division of Corporation Finance
Attention: Irene Paik, Joseph McCann, Franklin Wyman and Lisa Vanjoske
May 15, 2020
Re:
BriaCell Therapeutics Corp.
Amendment No. 7 to Registration Statement on Form F-1
Filed May 18, 2020
File No. 333-234292
Ladies and Gentlemen:
BriaCell Therapeutics Corp. (the “Company”) is hereby filing Amendment No. 7 to its Registration Statement on Form F-1/ Amendment No. 7 has been revised to reflect i) recent developments, ii) the Company’s financials for the fiscal quarter ended January 31, 2020 and iii) the assumed public offering price per Common Unit and Pre-funded Unit of $6.33 (the “Offering Price”). The Offering Price was not determined by any particular formula but rather through negotiations between the Company and the underwriter.
We hope the foregoing answers are responsive to your comments. Please do not hesitate to contact our counsel at (212) 930-9700 with any questions or comments regarding this correspondence.
Sincerely,
/s/
William V. Williams
Show Raw Text
CORRESP
1
filename1.htm
BriaCell
Therapeutics Corp.
Suite
300 – 235 West 15th Street
West
Vancouver, BC V7T 2X1
Securities
and Exchange Commission
100
F Street N.E.
Washington,
D.C. 20549
Division
of Corporation Finance
Attention:
Irene Paik, Joseph McCann, Franklin Wyman and Lisa Vanjoske
May
15, 2020
Re:
BriaCell
Therapeutics Corp.
Amendment
No. 7 to Registration Statement on Form F-1
Filed
May 18, 2020
File
No. 333-234292
Ladies
and Gentlemen:
BriaCell
Therapeutics Corp. (the “Company”) is hereby filing Amendment No. 7 to its Registration Statement on Form F-1/ Amendment
No. 7 has been revised to reflect i) recent developments, ii) the Company’s financials for the fiscal quarter ended January
31, 2020 and iii) the assumed public offering price per Common Unit and Pre-funded Unit of $6.33 (the “Offering Price”).
The Offering Price was not determined by any particular formula but rather through negotiations between the Company and the underwriter.
We
hope the foregoing answers are responsive to your comments. Please do not hesitate to contact our counsel at (212) 930-9700 with
any questions or comments regarding this correspondence.
Sincerely,
/s/
William V. Williams
William
V. Williams
cc:
(via email)
Jamieson
Bondarenko
Gadi
Levin
Gregory
Sichenzia, Esq.
Avital
Perlman, Esq.
Aaron
Sonshine
Virgil
Z. Hlus